Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.0290
Abstract: This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors who experienced disease progression after… read more here.
Keywords: receptor radionuclide; association upfront; progression; peptide receptor ... See more keywords
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.14493
Abstract: Key Points Question Among adults with type 2 diabetes (T2D), what is the efficacy, safety, and tolerability of the novel, orally administered, small molecule glucagon-like peptide 1 receptor agonist danuglipron? Findings In this phase 2… read more here.
Keywords: efficacy safety; like peptide; peptide receptor; glucagon like ... See more keywords
Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.16290
Abstract: This cohort study compares rates of 1-year adherence to glucagon-like peptide-1 receptor agonist or sodium-glucose cotransporter 2 inhibitor therapies by co-payment level among US adults with type 2 diabetes and/or heart failure. read more here.
Keywords: agonist sodium; peptide receptor; glucagon like; adherence glucagon ... See more keywords
Knocking down the sex peptide receptor by dsRNA feeding results in reduced oviposition rate in olive fruit flies.
Sign Up to like & getrecommendations! Published in 2020 at "Archives of insect biochemistry and physiology"
DOI: 10.1002/arch.21665
Abstract: Insect pests can cause crop damage in yield or quality, resulting in profit losses for farmers. The primary approach to control them is still the use of chemical pesticides resulting in significant hazards to the… read more here.
Keywords: insects; sex peptide; peptide receptor;
Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells **
Sign Up to like & getrecommendations! Published in 2022 at "ChemBioChem"
DOI: 10.1002/cbic.202100521
Abstract: Current immunotherapeutics often work by directing components of the immune system to recognize biomarkers on the surface of cancer cells to generate an immune response. However, variable changes in biomarker distribution and expression can result… read more here.
Keywords: cancer cells; activates formyl; peptide receptor; formyl peptide ... See more keywords
The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Genetics & Genomic Medicine"
DOI: 10.1002/mgg3.1194
Abstract: Relaxin/relaxin family peptide receptor 1 (RXFP1) signaling is important for both normal physiology and disease. Strong preclinical evidence supports relaxin as a potent antifibrotic molecule. However, relaxin‐based therapy failed in clinical trial in patients with… read more here.
Keywords: rxfp1; relaxin family; family peptide; peptide receptor ... See more keywords
Peptide Receptor Radiotherapy: Current Approaches and Future Directions
Sign Up to like & getrecommendations! Published in 2019 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0677-7
Abstract: Neuroendocrine neoplasia (NEN) represents a heterogenous group of tumours. Guidelines regarding treatment choice and sequencing remain complex given varied primary sites, hormone-secretory status, tumour grade, disease heterogeneity, and paucity of rigorous comparative trials due to… read more here.
Keywords: radiotherapy current; receptor radiotherapy; treatment; future directions ... See more keywords
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01037-7
Abstract: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on… read more here.
Keywords: radionuclide therapy; prrt; receptor radionuclide; receptor ... See more keywords
Peptide receptor radionuclide therapy after NETTER-1 clinical trial: what should not be left behind
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Imaging"
DOI: 10.1007/s40336-019-00327-2
Abstract: Peptide receptor radionuclide therapy (PRRT) is an established therapy that takes advantage of the over-expression of somatostatin receptors (SSTRs) on neuroendocrine tumor cell surface, to vehicle radioactivity on cancer tissues. Approximately 80% of neuroendocrine tumors… read more here.
Keywords: radionuclide; receptor radionuclide; therapy; radionuclide therapy ... See more keywords
Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological Reports"
DOI: 10.1007/s43440-021-00274-8
Abstract: Graphic abstract Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic… read more here.
Keywords: depression; glucagon like; treatment; receptor agonists ... See more keywords
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2020.07.017
Abstract: PURPOSE There are roughly 30 million Americans diagnosed with diabetes mellitus (DM), with nearly 95% of these cases being type 2 (T2)-DM. The American Diabetes Association continues to recommend metformin as the first-line initial treatment… read more here.
Keywords: semaglutide; glucagon like; receptor agonist; peptide receptor ... See more keywords